{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/ivabradine/","result":{"pageContext":{"chapter":{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine","depth":2,"htmlHeader":"<!-- begin field a6e543c7-ef1e-49bf-9d49-6a64eb21c5ce --><h2>Ivabradine</h2><!-- end field a6e543c7-ef1e-49bf-9d49-6a64eb21c5ce -->","summary":"","htmlStringContent":"<!-- begin item 9b7afa8c-3106-43b5-9508-3a034fc80c92 --><!-- end item 9b7afa8c-3106-43b5-9508-3a034fc80c92 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d8779658-2c30-5c2c-bade-e6494831e83f","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field e4e492bb-18ee-476c-859b-a6f7011d3a2c --><h3>Dose</h3><!-- end field e4e492bb-18ee-476c-859b-a6f7011d3a2c -->","summary":"","htmlStringContent":"<!-- begin item d88a43b2-f357-4a6f-84b2-a6f7011d3842 --><!-- begin field ab666c44-b78e-48ec-a431-a6f7011d3a2c --><ul><li>Do not start ivabradine if the resting heart rate is below 70 beats per minute. </li><li><strong>People aged 74 years or under</strong> — initially 5 mg twice daily for 3–4 weeks, then increased if necessary to 7.5 mg twice daily (if the dose is tolerated and heart rate remains above 60 beats per minute). <ul><li>Reduce the dose if it is not tolerated to 2.5–5 mg twice daily (the heart rate at rest should not be allowed to fall below 50 beats per minute).</li><li>If the heart rate decreases below 50 beats per minute, or the person experiences symptoms of bradycardia, reduce the dose including the lowest dose of 2.5 mg twice daily. <ul><li>Ivabradine should be stopped if the heart rate remains below 50 beats per minute or symptoms of bradycardia persist despite the dose reduction. </li></ul></li></ul></li><li><strong>People aged 75 years or over </strong>— initially 2.5 mg twice daily, increased if necessary (the heart rate at rest should not be allowed to fall below 50 beats per minute). </li><li>Ivabradine should be stopped if symptoms do not improve within 3 months.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016d</a>]</p><!-- end field ab666c44-b78e-48ec-a431-a6f7011d3a2c --><!-- end item d88a43b2-f357-4a6f-84b2-a6f7011d3842 -->","subChapters":[]},{"id":"96fb49e6-f02d-5d18-a69b-001cbd6c6acd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 56eccfce-460a-4eff-b4b7-fa4b9726eaf2 --><h3>Adverse effects</h3><!-- end field 56eccfce-460a-4eff-b4b7-fa4b9726eaf2 -->","summary":"","htmlStringContent":"<!-- begin item 76640368-f54e-475f-879f-bd19a012dca6 --><!-- begin field c3da47df-f116-4b2c-8a69-77223c4a8812 --><ul><li><strong>Eye disorders </strong>— visual disturbances such as blurred vision (common), luminous phenomena (phosphenes — brief spots or flashes of light) is very common. <ul><li>Phosphenes occur in about 15% of people taking ivabradine, usually starting within the first 2 months of treatment and resolving either on continued treatment or on stopping treatment.</li><li>People taking ivabradine should be advised to be careful when driving or using machines at times when there could be sudden changes in light intensity (especially when driving at night) if they experience luminous phenomena [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Servier Laboratories Limited, 2016</a>].</li></ul></li><li><strong>Bradycardia </strong>— occurs in around 4% of people taking ivabradine — monitor heart rate closely within the first 2–3 months of treatment.<ul><li>If heart rate decreases below 50 beats per minute at rest or the person experiences symptoms related to bradycardia such as dizziness, fatigue, or hypotension, reduce the dose.</li><li>If heart rate remains less than 50 beats per minute following a dose reduction, or symptoms of bradycardia persist, stop treatment with ivabradine.</li></ul></li><li><strong>Atrial fibrillation </strong>— people taking ivabradine should be regularly monitored for the occurrence of atrial fibrillation. If atrial fibrillation develops, treatment should be reviewed and the benefits and risks of ivabradine use should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2014</a>].</li><li><strong>Headache </strong>— this<strong> </strong>is a common, but is usually transient and resolves within the first month of treatment.</li><li><strong>Gastrointestinal disorders </strong>— nausea, constipation, diarrhoea and abdominal pain are uncommon adverse effects of ivabradine.</li><li>Other uncommon adverse effects include:<ul><li>Angioedema.</li><li>Dyspnoea.</li><li>Eosinophilia.</li><li>Muscle cramps.</li><li>Vertigo.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016d</a>]</p><!-- end field c3da47df-f116-4b2c-8a69-77223c4a8812 --><!-- end item 76640368-f54e-475f-879f-bd19a012dca6 -->","subChapters":[]},{"id":"6697f7d2-13a7-599f-b25d-10b75d6c5c4d","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field e824011b-9e18-4c6e-aacf-d835d5c5292a --><h3>Cautions and contraindications</h3><!-- end field e824011b-9e18-4c6e-aacf-d835d5c5292a -->","summary":"","htmlStringContent":"<!-- begin item 1fe34cd8-8acc-461e-af5e-3ccd23d27cfb --><!-- begin field 32e7ed6b-1137-448f-a0d3-593eeb81bbef --><ul><li><strong>Ivabradine is contraindicated in:</strong><ul><li>Acute myocardial infarction or unstable angina.</li><li>Severe hypotension (blood pressure less than 90/50 mmHg).</li><li>Sino-atrial block or 3rd degree AV block.</li><li>Severe hepatic insufficiency.</li><li>Unstable or acute heart failure.</li><li>Women who are pregnant or breastfeeding — data are lacking to support its use in these women.</li><li>People younger than 18 years of age — data are lacking to support its use in this population.</li><li>People with a pacemaker where the heart rate is imposed exclusively by the device.</li><li>People also taking a rate-limiting calcium-channel blocker (verapamil or diltiazem) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2014</a>].</li></ul></li><li><strong>Ivabradine should not be started in anyone with a resting heart rate less than 70 beats per minute</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2014</a>]<strong>.</strong></li><li><strong>Ivabradine should be used with caution in:</strong><ul><li>Atrial fibrillation.</li><li>People who have had a recent stroke.</li><li>2nd degree AV block. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016d</a>]</p><!-- end field 32e7ed6b-1137-448f-a0d3-593eeb81bbef --><!-- end item 1fe34cd8-8acc-461e-af5e-3ccd23d27cfb -->","subChapters":[]},{"id":"2aae5105-862f-5e1c-9b32-0bc494bc5a32","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 083a7709-5a5c-4f52-826b-8a21b8e9e651 --><h3>Drug interactions</h3><!-- end field 083a7709-5a5c-4f52-826b-8a21b8e9e651 -->","summary":"","htmlStringContent":"<!-- begin item 5c55af25-236c-4bd0-b280-1f6772cd8278 --><!-- begin field 3fa6214f-d40f-4fa7-8487-ff8e55b15b9d --><ul><li><strong>CYP3A4 inhibitors </strong>(such as azole antifungals [ketoconazole, itraconazole], macrolide antibiotics [clarithromycin, erythromycin], and protease inhibitors [nelfinavir, ritonavir]) — concomitant administration is contraindicated, as they may increase the plasma concentration of ivabradine, increasing the risk of bradycardia.<ul><li>Moderate CYP3A4 inhibitors (such as fluconazole) — the starting dose may need to be reduced to 2.5 mg twice daily and the heart rate monitored.</li></ul></li><li><strong>CYP3A4 inducers </strong>(such as rifampicin, barbiturates, phenytoin, and St John's Wort) — concomitant use may reduce plasma levels of ivabradine and require an adjustment of the dose of ivabradine. Concomitant use of St John's Wort should be avoided.</li><li><strong>Drugs which prolong the QT interval </strong>(such as quinidine, amiodarone, and erythromycin) — should not be given concomitantly with ivabradine, as QT prolongation may be exacerbated by the heart rate reduction caused by ivabradine.</li><li><strong>Grapefruit </strong>— the plasma concentration of ivabradine can increase by up to two-fold. People should avoid eating grapefruit or drinking grapefruit juice whilst taking ivabradine.</li><li><strong>Rate-limiting calcium-channel blockers </strong>— concomitant use of ivabradine with verapamil or diltiazem is not recommended, because it can result in excessive reduction of heart rate.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016d</a>]</p><!-- end field 3fa6214f-d40f-4fa7-8487-ff8e55b15b9d --><!-- end item 5c55af25-236c-4bd0-b280-1f6772cd8278 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}